Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities
Sponsor: Soleno Therapeutics, Inc.
Summary
This is a phase 2 open-label, one-arm, clinical study to evaluate the efficacy and safety of DCCR (diazoxide choline) extended-release tablets over 1 year of treatment, in patients with genetic obesities.
Official title: An Open-Label Study to Assess the Preliminary Efficacy and Safety of DCCR (Diazoxide Choline) Extended-Release Tablets in Patients With Genetic Obesities
Key Details
Gender
All
Age Range
5 Years - Any
Study Type
INTERVENTIONAL
Enrollment
0
Start Date
2023-01
Completion Date
2024-03
Last Updated
2026-10-13
Healthy Volunteers
No
Conditions
Interventions
DCCR (diazoxide choline) extended-release tablets
All participants will be titrated over a four week period to the maintenance dose. Participants will take DCCR daily for up to 52 weeks.